<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917525</url>
  </required_header>
  <id_info>
    <org_study_id>METC152045</org_study_id>
    <nct_id>NCT02917525</nct_id>
  </id_info>
  <brief_title>Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI</brief_title>
  <acronym>BASIK2</acronym>
  <official_title>Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early development of calcified aortic valve disease (CAVD) is a commonly occurring
      complication in patients with a bicuspid aortic valve (BAV, an aortic valve consisting of two
      leaflets instead of three). In general, CAVD is characterized by progressive narrowing of the
      aortic valve, with involvement of altered calcium metabolism. CAVD progression in fact may
      lead to necessity of valve replacement, since to date, no other therapies have been shown
      effective in the treatment of CAVD.

      The primary objective of our study is to test the hypothesis that supplementation of vitamin
      K2 will slow down the calcium metabolism in CAVD. Vitamin K2 is essential in the activation
      of matrix Gla Protein (MGP), an important inhibitory factor in the regulation of
      calcification.

      In this randomized controlled trial, 44 patients will be allocated to either the vitamin K2
      or placebo group. To assess the calcification process in a detailed manner in these patients,
      a Positron Emission Tomography (PET) scanner using a tracer (18F-fluoride [NaF]) that has
      been shown to bind to regions of newly developing microcalcification in aortic valve tissue
      is used.

      We expect that vitamin K2 supplementation will reduce the calcium metabolism in the aortic
      valve on 18NaF-PET (primary endpoint) and slow progression of CAVD as measured by the calcium
      score on CT and echocardiography after 18 months (secondary endpoints), when compared to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aortic valve calcium metabolism</measure>
    <time_frame>Measured at baseline and 6 months</time_frame>
    <description>Change in calcium metabolism, measured as uptake of the 18F-NaF tracer on a 18F-NaF PET/CMR scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aortic valve calcium score</measure>
    <time_frame>Measured at baseline, 6 and 18 months</time_frame>
    <description>Change in aortic valve calcium score, measured on CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of aortic valve stenosis</measure>
    <time_frame>Measured at baseline, 6, 12 and 18 months</time_frame>
    <description>Change of severity of aortic valve stenosis on echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Vitamin K2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22 patients will receive 360ug Vitamin K2 daily during 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>22 patients will receive placebo during 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2</intervention_name>
    <arm_group_label>Vitamin K2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known bicuspid aortic valve

          -  calcified mild to moderate aortic valve stenosis on prior echocardiography

          -  informed consent provided

        Exclusion Criteria:

          -  absence of calcified aortic valve stenosis on echocardiography

          -  presence of severe aortic valve stenosis

          -  history of aortic valve repair or replacement

          -  accepted atrial fibrillation

          -  use of oral anticoagulants

          -  claustrophobia

          -  presence of a pacemaker, ICD or ferromagnetic materials in the body

          -  life expectancy &lt;2 years

          -  Pregnancy (current or wish for near future)

          -  soy allergy

          -  use of vitamin K-containing supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bas Kietselaer, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bas Kietselaer, M.D., PhD</last_name>
    <phone>+31 (0)43 687 5096</phone>
    <email>b.kietselaer@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas Kietselaer, M.D., PhD</last_name>
      <phone>+31 (0)43 3875093</phone>
      <email>b.kietselaer@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bas Kietselaer, M.D. PhD</last_name>
      <phone>+31 (0)43 3875093</phone>
      <email>b.kietselaer@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Frederique Peeters, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcium metabolism</keyword>
  <keyword>Matrix Gla Protein</keyword>
  <keyword>Vitamin K2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

